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Abstract
This paper reports a case of severe cholestasis as an atypical manifestation of Graves’ 
disease. It discusses the pathophysiology, the diagnosis and the investigation of this 
complication of hyperthyroidism as well as the impact of this finding on the therapeutic 
options for managing the disease.
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Thyrotoxicosis is the clinical manifestation of an excessive release of 
thyroid hormones, associated or not with glandular hyperfunction. The main 
etiologies are Graves’ disease (GD), toxic adenoma, toxic multinodular goiter, 
subacute thyroiditis, and thyrotoxicosis factitia1. GD is the most common form 
of hyperthyroidism, accounting for 60% to 80% of cases, with a women-to-men 
ratio of 5 to 10 and a higher incidence among those aged 40 to 60 years1.
Initially described by Robert Graves in 1835, GD is an autoimmune disease 
which presents with some typical symptoms, such as weight loss, anxiety, 
tremors, ophthalmopathy and diffuse goiter2,3. However, in the past few 
decades, several atypical clinical manifestations have been reported, such as 
anemia, thrombocytopenia, acute myocardial infarction, and jaundice2. This 
report discusses the case of a patient with GD manifested as severe jaundice.
CASE REPORT
A 46-year-old male patient sought emergency care complaining of 
inappetence, dyspepsia, and weight loss of 16 kilograms over the course of 
4 months, followed by abdominal discomfort and sudden onset of jaundice. 
He reportedly did not smoke, drink alcohol or use illicit drugs. He also reported 
having experienced symptoms of proptosis, fatigue and eventual palpitation 
during the previous year, which compromised his daily activities. Thus, he was 
referred for hospital admission because of suspected periampullary tumor.
In medical history-taking, the patient reported an admission due to 
abdominal discomfort, jaundice and palpitation two years earlier. The patient 
was diagnosed with atrial fibrillation, for which amiodarone was prescribed. 
He then experienced a spontaneous resolution of his abdominal discomfort 
and jaundice, with no etiological definition at that time.
In the current admission, the patient presented with a cholestatic syndrome, 
and physical examination revealed tachycardia, fibroelastic diffuse goiter 
(approximately 50 g), no palpable nodules, a fine tremor of hands, palpebral 
retraction, bilateral ocular proptosis, periorbital edema, conjunctival hyperemia 
and chemosis. An investigation revealed the following laboratory test results: 
thyroid-stimulating hormone (TSH): 0.01 mIU/L (reference range: 0.35-4.94 mIU/L), 
free T4: 4.53 ng/dL (reference range: 0.7-1.8 ng/dL), TSH receptor antibodies 
(TRAb): 17.99 U/L (reference range: <1.5 U/L), and anti–thyroid peroxidase 
antibodies (anti-TPO): 155.10 U/mL (reference range: <15 U/ml). A thyroid 
ultrasonography revealed a diffuse gland enlargement with homogeneous 
echotexture as well as reactive cervical lymph nodes. Therefore, the patient was 
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diagnosed with hyperthyroidism due to GD. Cardiac 
evaluation was performed with an electrocardiogram 
(ECG), and a transthoracic echocardiogram confirmed 
high-response atrial fibrillation and mild left atrial 
dilation.
Amiodarone was suspended due to a possible 
hepatotoxicity and interference on thyroid function, 
and beta-blockers were administered. Concomitantly, 
an extensive investigation was performed in order 
to rule out primary liver diseases. Abdominal 
ultrasonography, abdominal computed tomography 
(CT), magnetic resonance cholangiography (MRC), 
and duodenoscopy did not reveal any hepatobiliary 
alterations. The laboratory evaluation showed negative 
serology for HIV, hepatitis A, B, and C viruses, 
anti-mitochondrial and anti-smooth muscle antibodies; 
ceruloplasmin level of 38.7 mg/dL (reference range: 
21-53 mg/dL); non-reactive anti-nuclear antibodies 
(ANA); ferritin level of 340 mg/dL (reference range: 
20-330 mg/dL); transferrin saturation index of 40% 
(reference range: 20-45%); alpha-1-antitrypsin level 
of 158 mg/dL (reference range: 90-200 mg/dL); 
immunoglobulin G (IgG) level of 1,645 mg/dL 
(reference range: 700-1,600 mg/dL); negative direct 
Coombs test.
Since severe cholestatic syndrome is a rare event 
in hyperthyroidism, as described by Wang et al.4, a 
percutaneous hepatic biopsy was performed to exclude 
other etiologies. The biopsy showed congestion 
of sinusoids, moderate inflammatory infiltrates, 
steatosis, and fibroblast foci, which constitute a set 
of nonspecific findings.
During hospitalization, the patient had variable 
liver test results (Table). At first, there was a reduction 
in the values after suspension of amiodarone, which 
suggested its involvement in the etiology of the case. 
However, that was followed by a new elevation in 
the results, thus refuting the hypothesis.
Because of the severe evolution of liver disease, 
the hypothesis that cholestasis was secondary to 
hyperthyroidism, the impossibility of treatment with 
tapazole and the presence of ophthalmopathy, the 
chosen approach was total thyroidectomy. Control 
of liver function and cholestasis was recovered after 
the procedure on April 12, 2018, and laboratory 
results were normal after 30 days, as shown in 
the Table.
DISCUSSION
The present study reports the case of a patient 
who presented with severe cholestatic syndrome 
secondary to GD. Although a study conducted by 
Gürlek et al. has demonstrated that the presence of 
hepatic impairment is found in 60% of patients with 
hyperthyroidism5, cases of severe cholestasis are rare 
(around 6.6%) in the literature4,6. Thus, in order to be 
sure that GD was the etiology of hepatic dysfunction 
in the current patient, other conditions had to be 
excluded through complementary laboratory tests, 
imaging tests and liver biopsy. Moreover, observing 
whether cholestasis would improve after appropriate 
treatment of thyrotoxicosis was necessary2.
Among the differential diagnoses for jaundice in 
patients with GD are the thyrotoxic crisis itself, the 
use of antithyroid drugs (thionamides), autoimmune 
hepatitis, primary biliary cholangitis (PBC), Gilbert’s 
syndrome, hepatic congestion secondary to heart 
failure, or thrombosis of the hepatic artery due to 
atrial fibrillation6. In addition, other common causes of 
hyperbilirubinemia unrelated to this thyroid disorder 
should be excluded, such as viral hepatitis, alcohol 
abuse, cholangitis, and other medications7.
There is no consensus regarding the mechanism 
of liver injury due to hyperthyroidism. The most 
accepted theory is that hypoxia occurs in centrilobular 
regions due to an increase in oxygen demand 
without adequate growth of hepatic blood flow6,8. 
Liver biopsy findings are nonspecific, consisting of 
mild lobular inflammatory infiltrate with neutrophils, 
eosinophils, and lymphocytes associated with Kupffer 
cell hyperplasia, as well as intrahepatic cytoplasmic 
cholestasis8.
Regarding treatment, total thyroidectomy was the 
best option for this patient instead of thionamides and 
radioactive iodine because of the liver dysfunction 
and ophthalmopathy. In Brazil, tapazole is the first 
therapeutic choice for GD. However, in the present 
case, hepatotoxicity inherent to thionamides limited 
their use9-11.
In conclusion, this case report draws attention 
to an unusual presentation of GD with hepatic 
dysfunction. Abnormal liver function test results are 
Table: Liver function test results during hospitalization.
TB/DB AST/ALT GGT ALP
(mg/dL) (U/L) (U/L) (U/L)
02/07 24.6/20 92/93 215 225
02/11 13.9/11.4 74/99 195 198
02/26 3.5/3.4 25/31 257 167
03/29 11.4/10.6 28/21 223 243
04/12 24/22.2 32/23 216 274
04/18 12.1/11.3 — — —
05/02 3.8/3.7 — — —
07/16 0.83/0.57 22/10 92 191
RR < 1.2/< 0.3 <37/<41 <73 <110
Total bilirubin (TB), direct bilirubin (DB), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), gamma-glutamyl transferase 
(GGT), alkaline phosphatase (ALP), reference range (RR).
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often observed in patients with hyperthyroidism, and 
clinicians should be aware of this situation. However, 
this patient presented with severe cholestasis, a rare 
condition that requires prompt diagnosis, etiological 
investigation and management. Appropriate diagnosis 
and treatment of hyperthyroidism was essential for 
improving the patient’s symptoms and liver dysfunction.
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